CD274 and hepatocellular carcinoma: However, the IMbrave150 trial demonstrated that compared to sorafenib, the combination of atezolizumab (PD-L1 inhibitor) and bevacizumab (VEGF inhibitor) conferred a superior survival benefit in patients with advanced HCC [7].